Vcanbio Cell & Gene Engineering Corp. (600645) Stock Overview

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and synthetic agents; and in vitro diagnostic reagents and medical devices. The company was founded in 1992 and is based in Tianjin, the People's Republic of China.